An Update on Clinical Trials in the Treatment of Advanced Hepatocellular Carcinoma-Reference-Cited by-同舟云学术

An Update on Clinical Trials in the Treatment of Advanced Hepatocellular Carcinoma

Published:2013-07 Issue:Supplement 1 Volume:47 Page:S16-S19
ISSN:0192-0790
Container-title:Journal of Clinical Gastroenterology
language:en
Short-container-title:

Author:

Lee Jean K.,Abou-Alfa Ghassan K.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Gastroenterology

Reference37 articles.

1. .Sorafenib in advanced hepatocellular carcinoma.;Llovet;N Engl J Med,2008

2. .BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAFMEKERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis.;Wilhelm;Cancer Res,2004

3. .Phase II study of sorafenib in patients with advanced hepatocellular carcinoma.;Abou-Alfa;J Clin Oncol,2006

4. .Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.;Cheng;Lancet Oncol,2009

5. .In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokineticpharmacodynamic relationship.;Mendel;Clin Cancer Res,2003

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Design, Synthesis and Evaluation of a Novel Teoptinib Derivative as an Effective Anti-hepatocellular Carcinoma Agent;Current Pharmaceutical Design;2024-08

2. Acteoside (Verbascoside): A Prospective Therapeutic Alternative against Hepatocellular Carcinoma by Inhibiting the Expression of AXL, FGFR, BRAF, TIE2 and RAF1 Targets;Combinatorial Chemistry & High Throughput Screening;2023-08

3. Targeted Therapies for Hepatocellular Carcinoma Treatment: A New Era Ahead—A Systematic Review;International Journal of Molecular Sciences;2022-11-15

4. Coupling HDAC4 with transcriptional factor MEF2D abrogates SPRY4-mediated suppression of ERK activation and elicits hepatocellular carcinoma drug resistance;Cancer Letters;2021-11

5. Epigenetic mechanisms of hepatocellular carcinoma progression: Potential therapeutic opportunities;Epigenetics and Metabolomics;2021